The US Food and Drug Term of office (FDA) approved 2 new labeling changes to include accusation on pediatric use — Corlopam (fenoldopam mesylate) insertion and Zemplar (paricalcitol) insertion.
Ketek (telithromycin) tablets, a new ketolide grade of anti-infectives, received FDA subject matter for the handling of community-acquired pneumonia (CAP), acute bacterial aggravation of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS).
This month’s structure reviews FDA new upshot approvals and labeling changes for:
Antihypertensive AgentsCorlopam (fenoldopam mesylate) Insertion
Anti-infective AgentsKetek (telithromycin) Tablets
Antipsychotic AgentsAbilify (aripiprazole) TabletsZyprexa (olanzapine) Shot
InsulinsApidra (insulin glulisine [rDNA origin]) Solution
Respiratory AgentsAdvair Diskus (fluticasone propionate/salmeterol xinafoate) Medication
Urologic AgentsProscar (finasteride) Tablets
This is a part of article May 2004 Taken from "Finasteride Propecia" Information Blog
No comments:
Post a Comment